imclone systems inc fda clears nd facility to manufacture erbitux imclone systems inc obtained approval from the food and drug administration for a second facility to manufacture the cancer drug erbitux more than doubling the new york companys production capacity construction of the square foot facility in branchburg n j was completed in the fourth quarter of and includes future capacity of as much as liters the other facility is also located on the branchburg campus 
